Dysregulation of metabolic flexibility: The impact of mTOR on autophagy in neurodegenerative disease

Over 400 million individuals worldwide are affected by neurodegenerative disorders and metabolic diseases.

• Metabolic disorders like diabetes mellitus are significant risk factors for neurodegenerative diseases.
• Current therapies for these conditions primarily focus on symptomatic care rather than disease progression.
• Targeting the mechanistic pathways associated with mTOR may offer new treatment strategies.
• Key pathways of interest include mTOR complex 1 (mTORC1), mTOR complex 2 (mTORC2), and AMP activated protein kinase (AMPK).
• Trophic factors, such as erythropoietin (EPO), and programmed cell death pathways may also play a role in treatment development.
• Further research is needed to ensure that mTOR pathway-based treatments can be safely applied in clinical settings.

AI simplified